Skip to content

Author

Nikki L. B. Freeman

We have 3 of 11 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Lipoprotein (a) Testing and Changes in Lipid-Lowering Therapy in Patients With ASCVD: Findings From the cvMOBIUS-2 Registry.

BACKGROUND Although the effectiveness of Lp(a) (lipoprotein[a])-lowering therapies remains under study, lipid guidelines now recommend Lp(a) testing in all adults to identify individuals who need more aggressive risk factor modification. Therefore, we evaluate contemporary patterns of Lp(a) testing and the impact of te...

Nishant P. Shah, P. Shrader, Nikki L. B. Freeman et al. · 0 citations
Open access Aug 2026

Event-Driven Intensification and Persistent Therapeutic Inertia in LDL-C Management Among 1,033,703 Patients With ASCVD

In ASCVD patients, LDL-C levels plateau well above guideline targets following an initial decline, and proactive, system-level monitoring and timely intervention are urgently needed to reduce cumulative above-goal LDL-C exposure.

S. Shoji, P. Shrader, Nikki L. B. Freeman et al. · 0 citations
Preprint Jul 2026

The Fidelity and Feedback Traps: The Case for Health Digital Twins as Modular Evolving Causal Systems

It is argued that health digital twins should be conceived as causally valid, modular, and evolving systems, and concluded that the standard for a health twin should be how well it supports decisions in the world it helps create, not how faithfully it reproduces the world it observes.

Nikki L. B. Freeman, Yating Zou, Kyungbok Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.